Eva van Doorn

473 total citations
11 papers, 244 citations indexed

About

Eva van Doorn is a scholar working on Epidemiology, Health and Immunology. According to data from OpenAlex, Eva van Doorn has authored 11 papers receiving a total of 244 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 4 papers in Health and 3 papers in Immunology. Recurrent topics in Eva van Doorn's work include Influenza Virus Research Studies (7 papers), Respiratory viral infections research (7 papers) and Vaccine Coverage and Hesitancy (4 papers). Eva van Doorn is often cited by papers focused on Influenza Virus Research Studies (7 papers), Respiratory viral infections research (7 papers) and Vaccine Coverage and Hesitancy (4 papers). Eva van Doorn collaborates with scholars based in Netherlands, Canada and Germany. Eva van Doorn's co-authors include Eelko Hak, Heng Liu, Anke Huckriede, Heng Liu, Henderik W. Frijlink, Stephen Norley, Emilia Bigaeva, Adam Meijer, Frederika Dijkstra and Tamar Ben-Yedidia and has published in prestigious journals such as PLoS ONE, Medicine and Vaccine.

In The Last Decade

Eva van Doorn

10 papers receiving 236 citations

Peers

Countries citing papers authored by Eva van Doorn

Since Specialization

Citations

This map shows the geographic impact of Eva van Doorn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva van Doorn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva van Doorn more than expected).

Fields of papers citing papers by Eva van Doorn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva van Doorn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva van Doorn. The network helps show where Eva van Doorn may publish in the future.

Co-authorship network of co-authors of Eva van Doorn

This figure shows the co-authorship network connecting the top 25 collaborators of Eva van Doorn. A scholar is included among the top collaborators of Eva van Doorn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva van Doorn. Eva van Doorn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Effectiviteit van influenzavaccinatie in Nederland 2017 ·Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Eva van Doorn, (unknown), Frederika Dijkstra, Maarten J. Bijlsma, Gé Donker, (unknown), (unknown), E. Hak, Adam Meijer	0
2	Influenza vaccine effectiveness estimates in the Dutch population from 2003 to 2014: The test-negative design case-control study with different control groups 2017 ·Vaccine ·Eva van Doorn, (unknown), Frederika Dijkstra, Gé Donker, Pier Paul Overduin, Adam Meijer, Eelko Hak	13
3	Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine 2017 ·Medicine ·Eva van Doorn, Heng Liu, Tamar Ben-Yedidia, Shimon Hassin, (unknown), Stephen Norley, Henderik W. Frijlink, Eelko Hak	39
4	Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial 2017 ·BMC Infectious Diseases ·Eva van Doorn, Olga Pleguezuelos, Heng Liu, Ana M. Fernández, (unknown), Gregory Stoloff, Fredrik Oftung, Stephen Norley, Anke Huckriede, Henderik W. Frijlink, Eelko Hak	30
5	[Effectiveness of influenza vaccine in the Netherlands: predominant circulating virus type and vaccine match are important conditions]. 2017 ·PubMed ·Eva van Doorn, (unknown), Frederika Dijkstra, Maarten J. Bijlsma, Gé Donker, (unknown), (unknown), E. Hak, Adam Meijer	1
6	Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes 2017 ·PLoS ONE ·(unknown), Frederika Dijkstra, Eva van Doorn, Maarten J. Bijlsma, Gé Donker, (unknown), (unknown), Eelko Hak, Adam Meijer	28
7	Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability 2016 ·PLoS ONE ·Emilia Bigaeva, Eva van Doorn, Heng Liu, Eelko Hak	29
8	Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project 2016 ·Vaccine ·Heng Liu, Henderik W. Frijlink, Anke Huckriede, Eva van Doorn, E.D. Schmidt, Odile Leroy, Guus F. Rimmelzwaan, (unknown), (unknown), Eelko Hak	10
9	Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review 2015 ·Human Vaccines & Immunotherapeutics ·Eva van Doorn, Heng Liu, Anke Huckriede, Eelko Hak	90
10	National Differences in Requirements for Ethical and Competent Authority Approval for a Multinational Vaccine Trial under the EU Directive 2001/20/EC 2015 ·Vaccines ·Eva van Doorn, Eelko Hak, Bob Wilffert	1
11	Steroid Receptor Proteins and Regulation of Growth in Mammary Tumors 1976 ·Breast Cancer ·Nicholas Bruchovsky, Eva van Doorn	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact